Lisa C Zaba, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Zaba’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A113192 · Current
Licensed to practise in California · since 2010 · expires 2028-07-31 · Cornell University Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$85,785
Medicare paid this office $85,785 for 318 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 124 | $32,319 | $126 |
| Long return visit (40+ min) | 65 | $14,478 | $159 |
| Return visit (30+ min) | 75 | $7,433 | $81 |
| New patient visit (60+ min) | 30 | $4,778 | $159 |
| Return visit (30+ min) | 42 | $4,574 | $99 |
See all 15 services
| Long return visit (40+ min) | 124 | $32,319 | $126 |
| Long return visit (40+ min) | 65 | $14,478 | $159 |
| Return visit (30+ min) | 75 | $7,433 | $81 |
| New patient visit (60+ min) | 30 | $4,778 | $159 |
| Return visit (30+ min) | 42 | $4,574 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $3,705 | $106 |
| New patient visit (45+ min) | 32 | $3,641 | $114 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,560 | $155 |
| Destruction of precancer skin growth, 1 growth | 39 | $2,236 | $49 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 61 | $1,318 | $15 |
| Punch biopsy, first skin growth | 26 | $1,024 | $39 |
| Biopsy of related skin growth, first growth | 23 | $754 | $29 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 35 | $554 | $15 |
| Punch biopsy, each additional skin growth | 12 | $343 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 29 | $221 | $2 |
Procedures Medicare counted
| Removal of skin lesions | 96 | More than 75% of doctors who do this |
| Skin biopsy | 86 | More than 74% of doctors who do this |
Who their Medicare patients are
318 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 12% · Women 49% · Also on Medicaid 17% · Health risk score 2.69. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 72% · Cancer 43% · Coronary heart disease 34% · Chronic kidney disease 33% · Diabetes 25% · Atrial fibrillation 25% · Heart failure 23% · Depression 16% · COPD 14% · Stroke 12% · Dementia 9%.
The office billed $299,132, Medicare allowed $111,726 and paid $85,785; for 1,090 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 318 | 1,090 | 75 | 2.69 | $299,132 | $85,785 |
| 2023 | 249 | 964 | 74 | 2.66 | $277,931 | $77,473 |
| 2022 | 272 | 1,194 | 73 | 2.68 | $285,688 | $71,461 |
| 2021 | 408 | 1,625 | 71 | 2.56 | $469,770 | $116,457 |
| 2020 | 477 | 1,699 | 73 | 2.48 | $519,444 | $110,573 |
| 2019 | 435 | 2,300 | 73 | 2.39 | $280,069 | $112,481 |
| 2018 | 91 | 300 | 71 | 2.00 | $40,904 | $18,245 |
| 2015 | 168 | 491 | 74 | 1.19 | $99,538 | $29,296 |
| 2014 | 26 | 84 | 70 | 1.27 | $13,970 | $4,359 |
| 2013 | 15 | 28 | 71 | 1.50 | $4,869 | $1,439 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Long return visit (40+ min) | 137 | $38,116 | $130 |
| Return visit (30+ min) | 97 | $11,472 | $87 |
| New patient visit (60+ min) | 36 | $5,845 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $4,607 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,478 | $160 |
| New patient visit (45+ min) | 24 | $2,946 | $123 |
| Destruction of precancer skin growth, 1 growth | 39 | $2,477 | $49 |
| Punch biopsy, first skin growth | 36 | $1,720 | $42 |
| Biopsy of related skin growth, first growth | 33 | $1,114 | $29 |
| Destruction of skin growth, 1-14 growths | 11 | $1,032 | $65 |
| Biopsy of related skin growth, each additional growth | 14 | $890 | $20 |
| Punch biopsy, each additional skin growth | 17 | $521 | $24 |
| Destruction of precancer skin growth, 2-14 growths | 27 | $321 | $2 |
2022: 15 services
| Long return visit (40+ min) | 103 | $23,828 | $121 |
| Return visit (30+ min) | 85 | $10,218 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $5,411 | $93 |
| Return visit (30+ min) | 49 | $5,092 | $77 |
| Long return visit (40+ min) | 27 | $4,776 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,496 | $180 |
| New patient visit (60+ min) | 27 | $4,172 | $155 |
| Destruction of precancer skin growth, 1 growth | 50 | $3,692 | $49 |
| New patient visit (45+ min) | 15 | $1,608 | $107 |
| Punch biopsy, first skin growth | 27 | $1,169 | $40 |
| Biopsy of related skin growth, first growth | 34 | $924 | $23 |
| Destruction of skin growth, 1-14 growths | 11 | $866 | $62 |
| Destruction of precancer skin growth, 2-14 growths | 39 | $592 | $2 |
| Destruction of precancer skin growth, 1 growth | 12 | $468 | $33 |
| Punch biopsy, each additional skin growth | 13 | $379 | $24 |
2021: 21 services
| Long return visit (40+ min) | 115 | $31,165 | $124 |
| Long return visit (40+ min) | 69 | $16,329 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 72 | $9,481 | $94 |
| Return visit (30+ min) | 78 | $8,563 | $91 |
| Return visit (30+ min) | 61 | $7,624 | $89 |
| New patient visit (60+ min) | 42 | $6,996 | $167 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $6,106 | $185 |
| New patient visit (60+ min) | 32 | $5,051 | $158 |
| New patient visit (45+ min) | 31 | $3,847 | $124 |
| Punch biopsy, first skin growth | 71 | $2,903 | $41 |
| New patient visit (45+ min) | 23 | $2,865 | $125 |
| Destruction of precancer skin growth, 1 growth | 33 | $2,482 | $51 |
| Destruction of precancer skin growth, 1 growth | 25 | $1,589 | $45 |
| Punch biopsy, first skin growth | 20 | $961 | $44 |
| Punch biopsy, each additional skin growth | 34 | $951 | $22 |
| Biopsy of related skin growth, first growth | 27 | $918 | $28 |
| Biopsy of related skin growth, first growth | 18 | $755 | $28 |
| Punch biopsy, each additional skin growth | 14 | $526 | $26 |
| Destruction of precancer skin growth, 2-14 growths | 27 | $411 | $2 |
| Biopsy of related skin growth, each additional growth | 13 | $354 | $19 |
| Destruction of precancer skin growth, 2-14 growths | 23 | $295 | $2 |
2020: 22 services
| Long return visit (40+ min) | 128 | $21,058 | $94 |
| Long return visit (40+ min) | 114 | $18,751 | $105 |
| Return visit (30+ min) | 109 | $10,158 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $9,087 | $98 |
| New patient visit (60+ min) | 50 | $7,478 | $150 |
| New patient visit (60+ min) | 45 | $7,096 | $158 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,269 | $188 |
| New patient visit (45+ min) | 45 | $5,194 | $115 |
| Return visit (30+ min) | 49 | $4,501 | $71 |
| New patient visit (45+ min) | 21 | $2,526 | $120 |
| Punch biopsy, first skin growth | 49 | $2,236 | $44 |
| Punch biopsy, first skin growth | 49 | $2,098 | $39 |
| Destruction of precancer skin growth, 1 growth | 41 | $2,042 | $43 |
| Destruction of precancer skin growth, 1 growth | 37 | $1,994 | $49 |
| Punch biopsy, each additional skin growth | 35 | $1,228 | $25 |
| Punch biopsy, each additional skin growth | 31 | $1,134 | $25 |
| Destruction of skin growth, 1-14 growths | 13 | $885 | $68 |
| Biopsy of related skin growth, first growth | 28 | $744 | $27 |
| Biopsy of related skin growth, first growth | 24 | $630 | $25 |
| Biopsy of related skin growth, each additional growth | 13 | $559 | $22 |
| Destruction of precancer skin growth, 2-14 growths | 34 | $318 | $2 |
| Destruction of precancer skin growth, 2-14 growths | 36 | $314 | $2 |
2019: 19 services
| Long return visit (40+ min) | 203 | $35,779 | $94 |
| New patient visit (60+ min) | 118 | $17,306 | $147 |
| Return visit (30+ min) | 123 | $11,573 | $68 |
| Destruction of precancer skin growth, 1 growth | 136 | $8,799 | $45 |
| New patient visit (45+ min) | 68 | $7,695 | $113 |
| Long return visit (40+ min) | 38 | $5,372 | $98 |
| Destruction of skin growth, 1-14 growths | 53 | $3,799 | $62 |
| Biopsy of related skin growth, first growth | 83 | $2,946 | $28 |
| Return visit (30+ min) | 32 | $2,829 | $71 |
| Punch biopsy, first skin growth | 50 | $2,186 | $42 |
| New patient visit (60+ min) | 14 | $1,892 | $135 |
| Biopsy of related skin growth, each additional growth | 42 | $1,657 | $21 |
| New patient visit (45+ min) | 13 | $1,494 | $115 |
| Destruction of precancer skin growth, 2-14 growths | 108 | $1,399 | $2 |
| Destruction of precancer skin growth, 1 growth | 14 | $956 | $46 |
| Punch biopsy, first skin growth | 18 | $793 | $44 |
| Punch biopsy, each additional skin growth | 21 | $723 | $25 |
| Biopsy of related skin growth, first growth | 12 | $306 | $24 |
| Destruction of precancer skin growth, 2-14 growths | 11 | $174 | $2 |
2018: 7 services
| Long return visit (40+ min) | 32 | $3,990 | $100 |
| New patient visit (60+ min) | 18 | $2,709 | $151 |
| New patient visit (45+ min) | 22 | $2,536 | $115 |
| Return visit (30+ min) | 19 | $1,652 | $72 |
| Destruction of precancer skin growth, 1 growth | 27 | $1,450 | $47 |
| Biopsy of single growth of skin and/or tissue | 28 | $1,050 | $35 |
| Destruction of precancer skin growth, 2-14 growths | 23 | $147 | $2 |
2015: 7 services
| New patient visit (30+ min) | 90 | $8,497 | $94 |
| Short return visit (20+ min) | 56 | $4,003 | $69 |
| Destruction of skin growth, 1-14 growths | 26 | $3,591 | $116 |
| Destruction of precancer skin growth, 1 growth | 53 | $3,030 | $55 |
| Biopsy of single growth of skin and/or tissue | 28 | $2,628 | $88 |
| Return visit (30+ min) | 19 | $2,004 | $105 |
| Destruction of precancer skin growth, 2-14 growths | 31 | $737 | $6 |
2014: 2 services
| Return visit (30+ min) | 11 | $1,680 | $67 |
| Short return visit (20+ min) | 12 | $729 | $43 |
Medicaid work
$530 in 2022
Medicaid paid $530 for 12 billed services this clinician did in 2022, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 12 | $530 |
| 2022 | 12 | 1 | 12 | $530 |
| 2021 | 55 | 1 | 19 | $2,436 |
| 2020 | 32 | 1 | 16 | $1,313 |
See the largest Medicaid services in earlier years
2021
| Long return visit (40+ min) | 55 | $2,436 |
2020
| Long return visit (40+ min) | 32 | $1,313 |
Drugs they prescribed that Part D paid
$25,689
Pharmacies billed $25,689 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 135) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
128 generic and fewer than 11 brand-name prescriptions · $25,689 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Triamcinolone Acetonide | 17 | $349 | $16 |
Year by year
| 2024 | 135 | 67 | 0% (0) | None | $25,689 |
| 2023 | 104 | 54 | 0% (0) | None | $4,957 |
| 2022 | 102 | 47 | 0% (0) | None | $14,217 |
| 2021 | 203 | 79 | None | 7% | $10,636 |
| 2020 | 223 | 89 | 0% (0) | 10% | $18,832 |
| 2019 | 378 | 151 | None | 11% | $41,852 |
| 2018 | 320 | 113 | 0% (0) | 18% | $101,815 |
| 2017 | 382 | 126 | 0% (0) | 26% | $88,611 |
| 2016 | 377 | 149 | 0% (0) | 28% | $55,264 |
| 2015 | 491 | 229 | 0% (0) | 13% | $51,379 |
| 2014 | 179 | 68 | 0% (0) | None | $24,564 |
| 2013 | 68 | 28 | 0% (0) | None | $5,167 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Triamcinolone Acetonide | 23 | $451 | $20 |
2022: 1 drug
| Triamcinolone Acetonide | 17 | $278 | $16 |
2021: 4 drugs
| Clobetasol Propionate | 12 | $1,409 | $117 |
| Triamcinolone Acetonide | 22 | $278 | $13 |
| Prednisone | 25 | $220 | $9 |
| Mupirocin | 11 | $136 | $12 |
2020: 4 drugs
| Triamcinolone Acetonide | 42 | $986 | $23 |
| Doxycycline Hyclate | 12 | $537 | $45 |
| Doxycycline Monohydrate | 12 | $231 | $19 |
| Prednisone | 18 | $179 | $10 |
2019: 9 drugs
| Clobetasol Propionate | 13 | $2,454 | $189 |
| Betamethasone Dipropionate | 24 | $2,053 | $86 |
| Triamcinolone Acetonide | 67 | $1,749 | $26 |
| Fluocinonide | 23 | $1,581 | $69 |
| Metronidazole | 11 | $1,389 | $126 |
| Doxycycline Hyclate | 15 | $1,185 | $79 |
| Mupirocin | 30 | $496 | $17 |
| Prednisone | 30 | $413 | $14 |
| Hydrocortisone | 24 | $358 | $15 |
2018: 9 drugs
| Fluorouracil | 24 | $4,225 | $176 |
| Betamethasone Diprop Augmented | 16 | $2,318 | $145 |
| Hydroxychloroquine Sulfate | 26 | $1,645 | $63 |
| Triamcinolone Acetonide | 28 | $1,568 | $56 |
| Fluocinonide | 11 | $989 | $90 |
| Prednisone | 20 | $606 | $30 |
| Cephalexin | 16 | $303 | $19 |
| Mupirocin | 19 | $188 | $10 |
| Hydrocortisone | 13 | $177 | $14 |
2017: 10 drugs
| Fluorouracil | 41 | $8,388 | $205 |
| Betamethasone Dipropionate | 39 | $6,850 | $176 |
| Fluocinonide | 25 | $2,550 | $102 |
| Mycophenolate Mofetil | 19 | $2,214 | $117 |
| Triamcinolone Acetonide | 25 | $1,551 | $62 |
| Hydroxychloroquine Sulfate | 24 | $1,423 | $59 |
| Prednisone | 38 | $1,250 | $33 |
| Doxycycline Monohydrate | 16 | $724 | $45 |
| Cephalexin | 22 | $471 | $21 |
| Sodium Chloride | 11 | $93 | $8 |
2016: 13 drugs
| Fluorouracil | 61 | $7,846 | $129 |
| Tacrolimus | 15 | $4,580 | $305 |
| Hydroxychloroquine Sulfate | 15 | $3,473 | $232 |
| Fluocinonide | 25 | $3,046 | $122 |
| Clobetasol Propionate | 14 | $2,994 | $214 |
| Betamethasone Dipropionate | 19 | $2,913 | $153 |
| Mycophenolate Mofetil | 18 | $2,715 | $151 |
| Triamcinolone Acetonide | 35 | $1,985 | $57 |
| Permethrin | 12 | $1,707 | $142 |
| Doxycycline Monohydrate | 25 | $1,518 | $61 |
| Prednisone | 28 | $1,178 | $42 |
| Hydrocortisone | 17 | $388 | $23 |
| Alendronate | 11 | $372 | $34 |
2015: 12 drugs
| Clobetasol Propionate | 45 | $10,245 | $228 |
| Fluorouracil | 55 | $7,323 | $133 |
| Doxycycline Hyclate | 40 | $6,423 | $161 |
| Fluocinonide | 49 | $4,651 | $95 |
| Desonide | 26 | $3,235 | $124 |
| Hydroxychloroquine Sulfate | 14 | $2,796 | $200 |
| Triamcinolone Acetonide | 81 | $2,021 | $25 |
| Mycophenolate Mofetil | 11 | $1,639 | $149 |
| Prednisone | 16 | $373 | $23 |
| Hydrocortisone | 20 | $243 | $12 |
| Alendronate | 12 | $198 | $17 |
| Fluconazole | 12 | $152 | $13 |
2014: 4 drugs
| Doxycycline Hyclate | 18 | $2,268 | $126 |
| Fluorouracil | 12 | $1,530 | $127 |
| Triamcinolone Acetonide | 18 | $1,264 | $70 |
| Clobetasol Propionate | 13 | $1,218 | $94 |
2013: 1 drug
| Triamcinolone Acetonide | 12 | $358 | $30 |
Money from drug and device companies
$5,175 in 2022
A payment is not proof that care is biased.
| EMD Serono | None | $5,175 | 3 payments
|
See all 3 published payments
| EMD Serono | Paid to speak or teach · 2022-10-12 | None | $1,725 |
| EMD Serono | Paid to speak or teach · 2022-08-26 | None | $1,725 |
| EMD Serono | Paid to speak or teach · 2022-08-02 | None | $1,725 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1710286398
- Licence
- CA A113192California A113192: Current · expires 2028-07-31
- Trained
- Js Weill Medical College, Cornell University, 2009
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-03-21
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2585 Samaritan Dr, San Jose, CA, 95124